LONDON. — A study from the University of Oxford found that the number of people who suffer from blood clots after being vaccinated with a coronavirus vaccine is about the same for those who receive Pfizer and Moderna, than those who are vaccinated. with AstraZeneca.
According to the study, 4 out of 1 million people experience cerebral venous thrombosis (CVD) after receiving the Pfizer or Moderna vaccine, compared to 5 out of 1 million people with the AstraZeneca vaccine.
The risk of getting TVC is much higher for those who get Covid-19 (39 in a million patients) than for those who get vaccinated.
The use of AstraZeneca vaccine has been stopped or limited in many countries due to blood clot problems.
The risk of cerebral vein thrombosis, which caused many regulators to stop or stop using the AstraZeneca and J&J vaccines, appears to be very similar for the AstraZeneca vaccine (5 in a million) than for in Pfizer and Moderna mRNA vaccines (4 in one million). pic.twitter.com/KZcMCIQVXd
– Sputnik V (@sputnikvaccine)
April 16, 2021
A disaggregated comparison of reported cases of CVD in patients with Covid-19 compared with cases of CVD in those who received a Covid-19 vaccine is:
In this study of more than 500,000 patients with Covid-19, CVD occurred in 39 of every million patients.
In more than 480,000 people who received an mRNA vaccine against Covid-19 (Pfizer or Moderna), TVC occurred in 4 in a million.
TVC has been reported to occur in approximately 5 out of every million people after the first dose of the AstraZeneca vaccine.
Compared to mRNA vaccines, the risk of a TVC for Covid-19 is approximately 10-fold higher.
Compared to the AstraZeneca vaccine, the risk of a TVC for Covid-19 is approximately 8 times greater.
However, they requested that all comparisons be interpreted with caution as the data are still being analyzed.
In conclusion:
The risk of suffering from TVC after the first dose of AstraZeneca is 5 out of every million vaccinated; that of having a cerebral venous thrombosis after a Pfizer or Moderna vaccine is 4 out of every million; that of suffering this rare thrombus in patients with covid, 39 of every million. For the study, 513,284 patients infected with coronavirus and 489,871 with a messenger RNA vaccine (Pfizer or Moderna) were considered. AstraZeneca risk data are as described by the EMA.